Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06090201

Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition

Cerebral microbleeds (CMBs) are haemosiderin deposits, resulting from the leakage of erythrocytes from small cerebral vessels, which can be detected noninvasively using susceptibility-sensitive magnetic resonance imaging (MRI) techniques. CMBs are commonly observed in daily practice: their prevalence range from five percent in healthy individuals over 65 years old to 50% in patients with a history of stroke. CMBs are associated with intracerebral hemorrhage (ICH) and also cognitive impairment and dementia.

The pathophysiology of CMBs is thought to primarily involve damage to brain microvasculature but the exact underlying cascade of events, including a potential role for haemostasis, has yet to be elucidated. Haemostatic defects (congenital or acquired) may contribute to an increased number and importance of CMBs. Congenital bleeding disorders such as haemophilia or von Willebrand disease (vWD), populations at high risk of ICH, are unique conditions that may give us further insights into a potential role of haemostatic defects in the pathophysiology of CMBs. CMBs might be the missing link between severe haemostatic defects, ICH risk and cognitive function.

We hypothesized that severe congenital haemostatic defects could contribute to an increased prevalence and number of CMBs, with an impact on cognition in adulthood.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, older than 18 years old, no upper age limit
  • Adult patients with a severe congenital haemostatic defect
  • Severe or moderate congenital haemophilia A (or B) defined as <5 IU/dL (<5%) endogenous FVIII (FIX) activity at screening
  • Severe von Willebrand disease defined as VWF: Act ≤15IU/dL (<15%) at screening
  • Ability of the participant to provide signed and dated informed consent

Exclusion criteria

  • Contraindication for brain MRI
  • HIV infection to avoid a bias towards severe multifactorial neurological complications
  • Other known coagulation disorder(s) in addition to haemophilia or von Willebrand disease
  • Lack of informed consent

Treatment and study plan

3-Tesla brain MRI and a comprehensive neuropsychological assessment

Other

Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.

Primary outcomes

  1. The rate of patients with at least one CMB on 3-Tesla brain MRI (using specific sequences dedicated to the detection of CMBs).

    Time frame: Within 3 Months after inclusion

Secondary outcomes

  1. Number and anatomical location (deep/lobar) of CMBs on 3-Tesla brain MRI

    Time frame: Within 3 Months after inclusion

  2. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • MoCA
  3. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    Memory: The free and cued selective reminding test (FCSRT, French version) ; The Wechsler digit span task will be used to examine verbal short term and working memory.

  4. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • Processing speed and attention: digit symbol coding subtest of WAIS 4; the Continuous Performance Test (third edition, CPT3).
  5. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • Executive function: The categorical and literal fluency test and the Trail-Making Test (TMT).
  6. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • Social cognition: MINI-SEA)
  7. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • Depression: CES-D
  8. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • Anxiety: HAM-A
  9. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • Fatigue: The Chalder Fatigue Scale
  10. Multi-domain cognitive performances assessed by standardized scales as follows

    Time frame: Within 3 Months after inclusion

    • Sleepiness and the impact of sleep disorders: The Epworth Sleepiness Scale

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Official study title

Cerebral Microbleeds in Severe Congenital Hemostatic Defects: Prevalence and Impact on Cognition

Acronym: HEMICOG

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Oct 19, 2023
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.